Kymera Therapeutics, Inc. vs Eli Lilly & Co.
KYMR vs LLY — side-by-side comparison from reported financials. KYMR leads 3, LLY leads 6 of 9 comparable metrics.
Kymera Therapeutics, Inc.
KYMR · Healthcare
$112.40+2.84%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | KYMR | LLY |
|---|---|---|
| Price | $112.40 | $1 177.20 |
| Market cap | $9.35B | $1.05T |
| Revenue (TTM) | $105M | $79.7B |
| Revenue growth | -5.8% | +31.7% |
| Net margin | -285.3% | 33.5% |
| Free cash flow | -$238M | $18.2B |
| Net cash (debt) | $766M | ($35.2B) |
| 1-year price return | +97.1% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | — | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -22% | 93% |
| Altman Z-score | 47.67 | 7.10 |
| CV checks passed | 4 of 9 | 11 of 9 |
| Employees | 273 | 50,000 |
Full résumé-style profiles: KYMR CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.